Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK012 in Advanced Triple Negative Breast Cancer
NCT00951054Phase 2Completed
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Feb 2009
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NK012 in triple-negative breast cancer (TNBC), sponsored by Nippon Kayaku Co., Ltd. Primary endpoint: Overall Response Rate. Started Feb 2009; status: completed.
02
Drugs
NK012
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00951054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951054.